Loading...

Fusen Pharmaceutical Company Limited

1652.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$0.39
HK$-0.01(-1.27%)

Fusen Pharmaceutical Company Limited (1652.HK) Stock Overview

Explore Fusen Pharmaceutical Company Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.8/100

Key Financials

Market Cap288.3M
P/E Ratio-1.39
EPS (TTM)$-0.28
ROE-0.42%
Fundamental Analysis

AI Price Forecasts

1 Week$0.37
1 Month$0.20
3 Months$0.44
1 Year Target$0.84

1652.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Fusen Pharmaceutical Company Limited (1652.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 55.42, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.84.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.39 and a market capitalization of 288.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

55.42RSI (14)
0.01MACD
35.78ADX
Stats data is not available for 1652.HKStats details for 1652.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1652.HKAnalyst Recommendations details for 1652.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.

CEO

Zhiming Cao

Employees

1,131

Headquarters

Urban Industrial Zone, Nanyang

Founded

2018

Frequently Asked Questions

;